Pseudarthrosis
Conditions
Brief summary
Septic pseudarthrosis of long bones are complications that can unfortunately occur after the consolidation of a fracture and some situations present risks of superinfection, persistent infection or mechanical failure (30-40% risk of complications) that can lead to amputation. A possible saving situation used by CRIOAC (Centre de Référence des Infections Ostéo-Articulaires Complexes) is the use of a bone substitute impregnated with an antibiotic allowing a high local concentration of this antibiotic. The aim of this study is to evaluate the cost of management of septic pseudarthrosis with two-stage treatment and CERAMENT® and the quality of life for this patients.
Interventions
OTHERQuestionnaire
The quality of life of patients will be measured.
OTHERCost evaluation
The cost for the hospital of the strategy of management will be evaluated.
Sponsors
Hospices Civils de Lyon
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
* age ≥ 18 years old * Diagnosis of septic pseudarthrosis * septic pseudarthrosis managed by the surgical technique using the CERAMENT bone substitute combined with an autograft / allograft by the Masquelet technique OR, for the comparative cohort: septic pseudarthrosis on long bone previously managed by the masquelet method without CERAMENT® * Medico-surgical management within the CRIOAC (Centre de Référence des Infections Ostéo-Articulaires Complexes) of the Croix-Rousse hospital in Lyon * Patient who was informed and did not object to participate in the study
Exclusion criteria
* Patient with a disability (deafness, language disorders) or whose mental or cognitive state does not allow to be informed and to express his opposition if necessary. * Patient with a disability (deafness, language impairment) or whose mental or cognitive state does not allow to understand the questions in the quality of life questionnaire * Patient participating in another quality of life study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cost evaluation | 24 months maximum | Estimation of the cost of care from the point of view of the hospital This estimation will be measured at the end of patient follow-up (usually between 12 and 24 months after antibiotic therapy disruption) |
Countries
France
Outcome results
None listed